In regions coendemic for P. vivax and P. falciparum, a unified treatment policy for malaria of
any parasitological cause is likely to confer the greatest individual and public health benefit …

Background Clinical effectiveness of previous regimens to treat Plasmodium vivax infection
have been hampered by compliance. We aimed to assess the dose–response, safety, and …

The continued success of efforts to reduce the global malaria burden will require sustained
funding for interventions specifically targeting Plasmodium vivax. The optimal use of limited …

Around half of the population of Afghanistan resides in areas at risk of malaria transmission.
Two species of malaria (Plasmodium vivax and Plasmodium falciparum) account for a high …

Background Primaquine is the only widely used drug that prevents Plasmodium vivax
malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to …

The relapsing peculiarity of Plasmodium vivax is one of the prime reasons for sustained
global malaria transmission. Global containment of P. vivax is more challenging and crucial …

Afghanistan's national guidelines recommend primaquine (PQ) for radical treatment of
Plasmodium vivax malaria, but this is rarely implemented because of concerns over …

Background Chloroquine has been recommended for Plasmodium vivax infections for> 60
years, but resistance is increasing. To guide future therapies, the cumulative benefits of …

Infection by Plasmodium vivax poses unique challenges for diagnosis and treatment.
Relatively low numbers of parasites in peripheral circulation may be difficult to confirm, and …

Recent successes in malaria control have put malaria eradication back on the public health
agenda. A significant obstacle to malaria elimination in Asia is the large burden of …